Immunohistochemical Study of p53 Expression in Colorectal Adenocarcinomas and its Clinicopathological Correlation
AbstractBackground: Colorectal carcinoma is the fourth most frequent cancer in men and the third in women worldwide. The identification of molecular markers that have a prognostic significance in colorectal carcinoma may have an impact on its treatment. This study aims to identify and evaluate the immunohistochemical expression of p53 in colorectal adenocarcinomas and to correlate its expression with various clinicopathological parameters. Methods: The present study was an observational study done in 30 surgical resection specimens received in the Department of Pathology, SRM Medical College and Research Centre, Kattankulathur, Tamil Nadu from June 2015-June 2017. Clinical history and clinicopathological parameters were obtained ,histomorphological and immunohistochemical evaluation was done and the results were correlated with clinicopathological variables. The IHC panel we used was mouse monoclonal p53 antibody (PathnSitu). Result: In our study, p53 overexpression was noted in 70% cases of colorectal adenocarcinomas. p53 overexpression was noted more in conventional adenocarcinomas (85.7%), more in left sided colonic carcinomas (71.4%), in advanced pT stage (57.1% in pT3) and also in cases with lymph node metastasis (57.1%). No statistically significant correlation of p53 with other clinicopathological variables such as age, gender, nature of specimen, tumor site, size, histological type, grade, tumor perforation, bowel wall invasion and perineural invasion were noted. Conclusion: Our study supports that p53 overexpression is an indicator of poor prognosis and may prove as an useful marker in identifying high risk patients who may benefit from adjuvant therapy in the early stage of disease.
Ferlay J, Soerjomataram I, Ervik M, Forman D, Bray F .GLOBOCAN 2012 .Estimated Cancer Incidence,Mortality and Prevalence World wide IARC Cancer Base, Lyon:IARC Press2012.Available from http://globocan iarc.fr.
Arnold M, Sierra MS, Laversanne M. Global patterns and trends in colorectal cancer incidence and mortality . Gut doi:10.1136/gutjnl-2015-310912 .
National Cancer Registry Programme. Population based cancer registries 2004-2005. New Delhi: Indian Council of Medical Research; 2008.
Gandhi V, Mehta K, Grover R, Pathak S, Aggarval BB; Multi targeted Approach To Treatment of Cancer, Part III, Chapter 13 -Prevalence of Gastrointestinal Cancers in India,. Springer Cham Heidelberg New York London. page 217-234
Manne U, Heisi L. Weiss, Russel B, et al. Nuclear accumulations of p53 in Colorectal Adenocarcinoma: Prognostic Importance differs with Race and Location of tumor. CANCER 1998; 83: 2456-67.
Ilyas M, Hao XP, Wilkinson K, et al .Loss of Bcl-2 expression correlates with tumor recurrence in colorectal cancer.Gut.1998;43:383-387.
Mardi K, Sharma M, Bhardwaj M, Rao M. p53 expression in colorectal carcinomas and its correlation with clinicopathological parameters. Clin Cancer Investig J. 2017;6:26-9
de Menezes HL, Juca MJ, de A Gomes EG, Benecio L Bulhoes BP Nunes, Coata HO, Delcio Matos. Analysis of immunohistochemical expressions of p53, Bcl-2 and Ki-67 in colorectal adenocarcinomas and their correlations with the prognostic factors. Arq. Gastroenterol. 2010;47:2
Georgescu CV, Saftoiu A, Georgescu CC , Ciurea R , Ciurea T. Correlations of Proliferation Markers, p53 Expression and Histological Findings in Colorectal Carcinoma. J. Gastrointestin Liver Dis .June 2007;16(2):133-139.
Shanmugam C, Katkoori VR, Jhala NC, Grizzle WE, Siegal GP, and Manne U. p53 Nuclear Accumulation and Bcl-2 Expression in Contiguous Adenomatous Components of Colorectal Adenocarcinomas Predict Aggressive Tumor Behavior. J Histochem Cytochem. 2008 Mar; 56(3): 305–312.
Prasad GR, Banda S. Evaluation of Immunoreactivity of p53 in Colorectal Adenocarcinomas. National Journal of Laboratory Medicine. 2017 Jan;6 (1): PO28-PO32.
Hegazy A, Daoud SA, Ibrahim WS, El-Atrebi K, SakerM and Abdel-Wahab N. Role of Ki-67, P53 and Bcl-2 in Advanced Colorectal Carcinoma (Histopathological and Immunohistochemical Study). Academic Journal of Cancer Research 2014; 7 (3): 168-172.
Compton CC, Fielding LP, Burgart LJ. Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979–994.
Compton CC, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors consensus conference: Colorectal Working Group. Cancer 2000; 88: 1739–1757.
Frank A. Sinicrope, San Bao Ruan, Karen R. Cleary, Clifton Stephens L, Jack Lee J , and Bernard Levin .bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. 1995;Cancer Res;55:237-241.
Washington MK, Berlin J, Branton P, et al .Members of the Cancer Committee, College of American Pathologists . Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum. Arch Pathol Lab Med. 2009 Oct; 133(10): 1539–1551.
Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA : Lymph node evaluation in colorectal cancer patients: A population-based study. J Natl Cancer Inst.2005; 97: 219-225.
Betge J, Pollheimer MJ, Lindtner RA, et al : Intramural and extramural vascular invasion in colorectal cancer: Prognostic significance and quality of pathology reporting. Cancer 2012;118: 628-638.
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R. Effector Memory T cells, Early metastasis, And Survival In Colorectal cancer. N. Engl.J.Med. 2005 ;353:2654–2666.
Mulder J.W.R, Baas I.O , Polak M.M, Goodman S.N and Offerhaus G.J.A, Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Brit.J.Cancer 1995;71:1257-1262.
Belluco C, Guillem J.G, Kemeny N, et al .p53 nuclear protein overexpression in colorectal cancer:a dominant predictor of survival in patients with advanced hepatic metastasis.J.clin.Oncol.1996;14:2696-2701.
Buglioni S, D'Agnano I, Cosimelli M, et al . Evaluation of multiple Bio-Pathological Factors in Colorectal Adenocarcinomas: Independent Prognostic Role of p53 and BCL-2. Int.J.Cancer (Pred Oncol).1999;84:545-552.
Ashar KM, Patel SC. Correlation of proliferative marker (Ki67), p53 expression and histomorphology in colorectal carcinoma. International Journal of Biomedical and Advance Research 2016; 7(12): 597-603.
Lanza G, Maestri I, Dubini A, et al .p53 Expression in Colorectal Cancer Relation to Tumor Type, DNA Ploidy Pattern, and Short-Term Survival. Am J Clin Pathol 1996;105:604-612.
Ofner D, Maier H, Riedmann B, et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol: Mol Pathol 1995;48:M12-M16.
Poller DN, Baxter KJ, Shepherd NA. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87–93.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).